Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | GSR | P00390 | 1/20 | 0.32 |
| ▸ | CDK4 | P11802 | 1/20 | 0.31 |
| ▸ | CCND1 | P24385 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22747529 | 0.77 | GABRA1 (0.37) | — | |
| SCHEMBL18876078 | 0.77 | MEN1 (0.34) | MEN1NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL27364173 | 0.76 | ESR1 (0.38) | GSR | |
| SCHEMBL18876100 | 0.76 | MEN1 (0.33) | MEN1NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL27259761 | 0.76 | — | — | |
| SCHEMBL18876144 | 0.76 | MEN1 (0.33) | MEN1NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL27316214 | 0.72 | KCNN4 (0.32) | MEN1NPC1RAB9AKMT2A | |
| SCHEMBL18876147 | 0.72 | LMNA (0.35) | MEN1NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL22843367 | 0.70 | TAS1R3 (0.30) | — | |
| SCHEMBL25880543 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10597364-B2 | Anthelmintic compounds, compositions and method of using thereof | Boehringer Ingelheim Animal Health USA Inc. (US) | 2020-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10597364-B2 | Anthelmintic compounds, compositions and method of using thereof | CYP8B1, CYP2C8, CYP2B6 | MEN1 4477/4885NPC1 1401/4885RAB9A 2537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.